Liquidia (NASDAQ:LQDA) Posts Earnings Results, Misses Expectations By $0.18 EPS

Liquidia (NASDAQ:LQDA) announced its earnings results on Thursday. The company reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18), FiscalAI reports. Liquidia had a negative net margin of 43.53% and a negative return on equity of 237.79%. The business had revenue of $92.02 million during the quarter. Liquidia’s revenue was up 3072.4% compared to the same quarter last year.

Here are the key takeaways from Liquidia’s conference call:

• Liquidia reported strong commercial profitability with full‑year 2025 net product sales of $148.3M (Q4 $90.1M), non‑GAAP adjusted EBITDA of $27.3M, net income of $14.6M, and approximately $190.7M cash after generating $33M positive cash flow in Q4.
• The launch momentum remains robust: >3,600 unique referrals and >2,900 patient starts through Feb‑28, and estimated inhaled‑treprostinil revenue share rising from ~10% in Q3 to ~17% in Q4, with 75% of starts prostacyclin‑naïve.
• Management plans multiple near‑term clinical programs to expand use and labeling (switch studies from oral/inhaled prostacyclins, adjunctive combinations, new indications like systemic sclerosis‑associated Raynaud’s and PH‑COPD) and will advance the next‑gen L‑606 pivotal study — all expected to be funded by operating cash flow and target building a >$1B franchise by 2027.
• Company downplays competitive threats from a recently announced soft‑mist inhaler (SMI) and new oral agents, arguing limited clinical/tolerability advantage for rivals, but competitor data are still evolving so the market impact remains uncertain.
• No new update on the ongoing IP/legal matter since the post‑trial briefing; management says it is confident but a judicial opinion timing is uncertain, representing potential downside risk if unfavorable.

Liquidia Stock Performance

NASDAQ LQDA opened at $36.03 on Friday. Liquidia has a 12-month low of $11.26 and a 12-month high of $46.67. The business’s 50 day moving average is $37.10 and its two-hundred day moving average is $30.89. The stock has a market capitalization of $3.13 billion, a price-to-earnings ratio of -43.41, a PEG ratio of 0.60 and a beta of 0.52. The company has a current ratio of 2.20, a quick ratio of 1.96 and a debt-to-equity ratio of 6.19.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Commercial momentum and profitability — Liquidia reported YUTREPIA net product sales of $90.1M in Q4 and $148.3M for 2025, achieved a second consecutive profitable quarter (Q4 net income $14.6M) and positive adjusted EBITDA, signaling rapid launch adoption and improving unit economics. GlobeNewswire Release
• Positive Sentiment: Balance sheet strength — the company ended 2025 with ~$190.7M in cash, improving liquidity and backing management’s plan to fund commercial expansion and clinical programs from operations. Quiver Quant Summary
• Positive Sentiment: Analyst upgrades and higher price targets — several firms raised ratings/targets after the quarter (HC Wainwright to $55, Needham to $54, BTIG to $50, Wells Fargo to $44), which supports further upside and likely contributed to intraday buying. Benzinga Analyst Roundup
• Neutral Sentiment: Mixed EPS headlines — Liquidia reported GAAP EPS of $0.15 for Q4. That missed some sell‑side consensus figures (~$0.33) but beat other estimates (Zacks cited $0.08), creating mixed investor interpretation of the results. Zacks Coverage
• Neutral Sentiment: Earnings materials and management commentary available — the slide deck and transcript provide color on commercial adoption, prescriber metrics and plans to fund L606 and other programs; useful for assessing sustainability of the launch. Earnings Presentation (Seeking Alpha)
• Negative Sentiment: Initial market reaction to the EPS headline — shares gapped down on the earnings headline before rebounding, showing sensitivity to EPS versus revenue/profitability nuance. That initial gap indicates headline risk if future quarters miss expectations. DefenseWorld: Gap Down
• Negative Sentiment: Insider and institutional sales — recent filings and summaries show notable insider sell activity and some large institutional reductions, which can weigh on sentiment if sustained. Fool: SEC Filing

Insiders Place Their Bets

In related news, CFO Michael Kaseta sold 36,932 shares of Liquidia stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $1,382,364.76. Following the transaction, the chief financial officer owned 350,919 shares in the company, valued at approximately $13,134,898.17. This trade represents a 9.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rajeev Saggar sold 21,142 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $791,345.06. Following the sale, the insider directly owned 176,883 shares of the company’s stock, valued at approximately $6,620,730.69. This trade represents a 10.68% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 212,534 shares of company stock worth $7,964,719. Corporate insiders own 26.50% of the company’s stock.

Institutional Trading of Liquidia

A number of institutional investors have recently modified their holdings of the company. Covestor Ltd raised its holdings in Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after buying an additional 359 shares during the period. PNC Financial Services Group Inc. grew its stake in Liquidia by 7.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company’s stock worth $217,000 after buying an additional 422 shares during the period. Whitcomb & Hess Inc. increased its position in shares of Liquidia by 2.0% in the third quarter. Whitcomb & Hess Inc. now owns 28,385 shares of the company’s stock worth $645,000 after acquiring an additional 558 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Liquidia in the fourth quarter worth $25,000. Finally, ProShare Advisors LLC raised its stake in shares of Liquidia by 7.1% in the 4th quarter. ProShare Advisors LLC now owns 11,756 shares of the company’s stock valued at $405,000 after acquiring an additional 775 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on LQDA shares. BTIG Research boosted their price target on Liquidia from $49.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday. Zacks Research cut Liquidia from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research note on Thursday, January 22nd. Raymond James Financial restated a “strong-buy” rating on shares of Liquidia in a research note on Thursday. Finally, Wells Fargo & Company increased their price target on Liquidia from $31.00 to $44.00 and gave the stock an “overweight” rating in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $42.00.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).